التفاصيل البيبلوغرافية
| العنوان: |
Future perspectives in melanoma research: Meeting report from the “Melanoma Bridge”. Napoli, December 1st–4th 2015 |
| المؤلفون: |
Ascierto, Paolo, Agarwala, Sanjiv, Botti, Gerardo, Cesano, Alessandra, Ciliberto, Gennaro, Davies, Michael, Demaria, Sandra, Dummer, Reinhard, Eggermont, Alexander, Ferrone, Soldano, Fu, Yang, Gajewski, Thomas, Garbe, Claus, Huber, Veronica, Khleif, Samir, Krauthammer, Michael, Lo, Roger, Masucci, Giuseppe, Palmieri, Giuseppe, Postow, Michael, Puzanov, Igor, Silk, Ann, Spranger, Stefani, Stroncek, David, Tarhini, Ahmad, Taube, Janis, Testori, Alessandro, Wang, Ena, Wargo, Jennifer, Yee, Cassian, Zarour, Hassane, Zitvogel, Laurence, Fox, Bernard, Mozzillo, Nicola, Marincola, Francesco, Thurin, Magdalena |
| بيانات النشر: |
BioMed Central Ltd. |
| سنة النشر: |
2016 |
| المجموعة: |
BioMed Central |
| الوصف: |
The sixth “Melanoma Bridge Meeting” took place in Naples, Italy, December 1st–4th, 2015. The four sessions at this meeting were focused on: (1) molecular and immune advances; (2) combination therapies; (3) news in immunotherapy; and 4) tumor microenvironment and biomarkers. Recent advances in tumor biology and immunology has led to the development of new targeted and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS) of cancer patients. Immunotherapies in particular have emerged as highly successful approaches to treat patients with cancer including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), bladder cancer, and Hodgkin’s disease. Specifically, many clinical successes have been using checkpoint receptor blockade, including T cell inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death-1 (PD-1) and its ligand PD-L1. Despite demonstrated successes, responses to immunotherapy interventions occur only in a minority of patients. Attempts are being made to improve responses to immunotherapy by developing biomarkers. Optimizing biomarkers for immunotherapy could help properly select patients for treatment and help to monitor response, progression and resistance that are critical challenges for the immuno-oncology (IO) field. Importantly, biomarkers could help to design rational combination therapies. In addition, biomarkers may help to define mechanism of action of different agents, dose selection and to sequence drug combinations. However, biomarkers and assays development to guide cancer immunotherapy is highly challenging for several reasons: (i) . |
| نوع الوثيقة: |
report |
| اللغة: |
English |
| العلاقة: |
http://www.translational-medicine.com/content/14/1/313Test |
| الإتاحة: |
http://www.translational-medicine.com/content/14/1/313Test |
| حقوق: |
Copyright 2016 The Author(s) |
| رقم الانضمام: |
edsbas.D860ADDE |
| قاعدة البيانات: |
BASE |
